GeoVax Labs (GOVX) Stock Price, News & Analysis

Company Overview

GeoVax Labs, Inc. is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs. This dual approach is designed to stimulate both cellular and humoral immunity, a feature that has supported advancement of the company’s HIV vaccine candidate through Phase 2 clinical trials. GeoVax is also applying this platform to develop next-generation vaccines for hemorrhagic fever viruses and novel coronaviruses, targeting populations in regions prone to outbreaks as well as frontline health workers.

Founded in 2001 and headquartered in Atlanta, Georgia, GeoVax operates in collaboration with academic institutions, government agencies and non-profit organizations. The company has received funding and technical support from the National Institutes of Health (NIH), the U.S. Department of Defense and other global health partners. These collaborations have advanced preclinical programs and facilitated clinical trial design, positioning GeoVax to rapidly respond to emerging infectious disease challenges.

Leadership at GeoVax is headed by President and Chief Executive Officer James W. Bunn, who brings more than two decades of experience in biotechnology operations and clinical development. Under his direction, the management team continues to refine the company’s vaccine platform and expand its pipeline. GeoVax’s board of directors and scientific advisory board comprise experts in virology, immunology and vaccine development, guiding strategic decisions as the company advances toward late-stage clinical studies and potential licensing partnerships.

Key Stats

• Today's Range: $2.13 to $2.40
• 50-Day Range: $1.05 to $3.64
• 52-Week Range: $0.96 to $34.75
• Volume: 2.02 million shs
• Average Volume: 14.68 million shs
• Market Capitalization: $7.21 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $150.00
• Consensus Rating: Reduce

GeoVax Labs Stock Analysis - MarketRank™

GeoVax Labs scored higher than 48% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Reduce

Consensus Rating

GeoVax Labs has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

GeoVax Labs has a consensus price target of $150.00, representing about 7,128.9% upside from its current price of $2.08.

Amount of Analyst Coverage

GeoVax Labs has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for GeoVax Labs are expected to grow in the coming year, from ($8.69) to ($3.07) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of GeoVax Labs is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of GeoVax Labs is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

GeoVax Labs has a P/B Ratio of 0.94. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

13.64% of the float of GeoVax Labs has been sold short.

Short Interest Ratio / Days to Cover

GeoVax Labs has a short interest ratio ("days to cover") of 0.56, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in GeoVax Labs has recently increased by 85.17%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

GeoVax Labs does not currently pay a dividend.

Dividend Growth

GeoVax Labs does not have a long track record of dividend growth.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 0.42

News Sentiment

GeoVax Labs has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.82 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for GeoVax Labs this week, compared to 2 articles on an average week.

Search Interest

30 people have searched for GOVX on MarketBeat in the last 30 days. This is an increase of 900% compared to the previous 30 days.

MarketBeat Follows

7 people have added GeoVax Labs to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, GeoVax Labs insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.57% of the stock of GeoVax Labs is held by insiders.

Percentage Held by Institutions

6.09% of the stock of GeoVax Labs is held by institutions.

Company Calendar

• Last Earnings: 4/15/2026
• Today: 6/02/2026
• Next Earnings (Estimated): 7/27/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GOVX
• CIK: 832489
• Web: www.geovax.com
• Phone: (678) 384-7220
• Fax: 678-384-7281
• Employees: 10
• Year Founded: 2001

Price Target and Rating

• Average Price Target for GeoVax Labs: $150.00
• High Price Target: $150.00
• Low Price Target: $150.00
• Potential Upside/Downside: +6,952.2%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($19.12)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$21.47 million
• Net Margins: N/A
• Pretax Margin: -2,508.10%
• Return on Equity: -709.52%
• Return on Assets: -399.33%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.06
• Quick Ratio: 1.06

Sales & Book Value

• Annual Sales: $852.28 thousand
• Price / Sales: 8.67
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.21 per share
• Price / Book: 0.96

Miscellaneous

• Outstanding Shares: 3,473,000
• Free Float: 3,449,000
• Market Cap: $7.39 million
• Optionable: Not Optionable
• Beta: 3.36